INTRODUCTION {#sec0005}
============

Parkinson's disease (PD) is a progressive neurodegenerative condition with age being the main risk factor for its development \[[@ref001]\]. With longevity having increased in most Western countries, a conservative estimation in 2007 predicted that the global number of PD patients will increase to approximately 10 million by 2030 \[[@ref002]\]. By 2010, there were approximately 630,000 PD patients in the USA, a figure that was thought set to double by 2040 \[[@ref003]\]. However, recent figures suggest these striking predictions may themselves be substantial underestimates since the incidence rates for PD now appear to be increasing each decade \[[@ref004]\]. While these figures are alarming in themselves, especially given the burden to patients and to their families, these demographics also demonstrate the massive impact on each country's healthcare services that PD brings.

For example, the costs in the USA of managing PD were estimated in 2013 at \$23 million, which is \$38,000 per patient per year \[[@ref005]\], a figure to which must be added the additional \$10,000 per patient/family of indirect costs that their PD incurs them. Furthermore, PD patients get progressively more expensive to manage as their condition deteriorates over time. Accordingly, increasing annual healthcare costs per PD patient are associated with more advanced stages of the disease, with greater burden resulting from cognitive decline, increased non-motor symptoms and development of balance impairment and falls. Therefore there is a compelling need, shared by patients, families and healthcare systems alike, to identify a cost-effective approach to intercept disease progression, to slow, stop or even reverse neurodegeneration in a rapidly expanding global population of PD patients. It is projected that if PD disease progression could be slowed by just 20% it would overall save approximately \$76,000 per patient, rising to a saving of approximately \$440,000 per patient if PD progression could be stopped altogether \[[@ref005]\]. Both these scenarios would translate to far better long-term quality of life for PD patients, as well as saving billions of healthcare dollars every year by all major Western countries. Currently, only symptomatic treatments are available to PD patients since no disease-modifying therapy has yet been demonstrated to be effective in slowing PD progression, which highlights what is currently a huge unmet need for the identification of effective neuroprotective PD therapeutics.

For this reason, the International PD Linked Clinical Trials initiative was established in 2012 with the specific aim of identifying disease-modifying treatments for PD that would slow, stop or reverse the neurodegenerative aspects of this condition. The International PD Linked Clinical Trials is run by a committee of 15 global PD experts who, under the stewardship of the Cure Parkinson's Trust, are tasked with selecting, and sending into appropriately-designed clinical trials, compelling new and repurposed therapeutics to evaluate their disease-modifying potential in various different populations of patients with PD. At their first ever committee meeting in 2012, 26 potential disease-modifying candidate drug approaches for slowing PD progression were evaluated. At that meeting, several of these therapeutics were prioritized to enter PD disease-modifying trials, and they have since entered, or have now recently completed (Bydureon), these clinical evaluations. On the basis of compelling biochemical, physiological and pharmaceutical arguments, coupled with a strong safety record, *Simvastatin* was one of the drugs prioritized at that meeting \[[@ref006]\]. Accordingly, funds were subsequently raised and this *Simvastatin* clinical trial in PD patients was commenced in September 2015 \[[@ref007]\]. This Simvastatin study is co-funded by the Cure Parkinson's Trust and the JP Moulton Foundation. This on-going 2 year trial involves 198 patients with mid-stage idiopathic PD and is currently being carried out in movement disorder units in 23 hospitals across the UK. Projected completion of this trial is in early 2020.

The current paper discusses the original biochemical, physiological and pharmaceutical rationale that led the committee in 2012 to agree that this trial was strongly merited to explore the disease-modifying potential of *Simvastatin* for treating PD. It also updates to October 2017 the rationale for conducting this trial in terms of our current understanding of the relevant mechanisms of action and biological targets of *Simvastatin* that continues to maintain our enthusiasm about the use of this therapeutic as a disease-modifying approach for patients with PD.

This paper also strives to achieve a balanced view of a range of conflicting epidemiological studies surrounding the use of statins for cardiovascular protection, and whether statin use for this purpose may increase or decrease PD risk.

Finally, this paper describes details about our ongoing *Simvastatin* trial and outlines the decisions made about its design, as well as aspects about patient selection, patient recruitment, the dose of *Simvastatin* chosen, investigator site selection, rationale on how the duration of the trial was chosen, and the choices of which patient outcomes are being measured.

WHY DOES SIMVASTATIN REPRESENT A STRONG CANDIDATE TO BE A DISEASE-MODIFYING THERAPEUTIC FOR PATIENTS WITH PARKINSON'S DISEASE? {#sec0010}
==============================================================================================================================

What is the biochemical, physiological & pharmaceutical rationale for testing Simvastatin in PD patients as a long-term disease-modifying therapy? Although statins have been widely adopted in millions of patients worldwide as cholesterol lowering drugs to reduce cardiovascular risk, a very wide range of laboratory studies (described below) coalesce to suggest that statins also modulate some of the important biochemical processes involved with driving neurodegenerative changes, and may therefore offer a beneficial long-term disease-modifying therapeutic approach to reduce neurological decline in PD patients.

Several laboratory studies have demonstrated multiple biochemical neuroprotective effects of statins in models of PD; these will be reviewed and discussed below. *Simvastatin*, like all statins, is a specific inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, and it is one of the most effective of the statins in terms of crossing the blood-brain barrier, while *Pravastatin* shows almost no penetration \[[@ref008]\]. In fact the permeability of different statins into the brain directly relates to the level of their individual lipophilicity \[[@ref009]\].

In addition to their original pharmaceutical use in lowering cholesterol, statins display multiple neuroprotective effects. For example, Selley \[[@ref011]\] reported that *Simvastatin* prevents methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal dopamine depletion and protein tyrosine nitration in mice. Ghosh et al. \[[@ref012]\] then found, at a dose of 1 mg/kg body weight/day (which is equivalent to the FDA--approved dose in adults), that *Simvastatin* enters the substantia nigra, inhibits the activation of p21(ras), suppresses the activation of NF-B, attenuates the expression of proinflammatory molecules, protects dopaminergic neurons, restores striatal fibers and dopamine levels, and improves locomotor function in an acute MPTP model of PD. They concluded by suggesting that statins are capable of slowing down the progression of neuronal loss in the MPTP mouse model.

In an excellent and extensive review, Roy and Pahan in 2011 \[[@ref013]\] outlined the evidence for five separate pathways, each thought to be of relevance in PD neurodegenerative aetiopathogenesis, by which *Simvastatin* may improve dopaminergic neuronal survival:-•suppression of proinflammatory molecules and microglial activation•stimulation of endothelial nitric oxide synthase•inhibition of oxidative stress•attenuation of α-synuclein aggregation•modulation of adaptive immunity

One of the objectives of the current review is to update these biochemical and pharmaceutical findings to the present day to help give a perspective on the rationale of why a clinical trial testing *Simvastatin* as a potential disease-modifying therapeutic for patients with PD is currently underway. Below is our current interpretation (updated to October 2017) of the multiple cholesterol-independent biochemical mechanisms of action of *Simvastatin* as originally cited by Roy and Pahan in 2011 \[[@ref013]\] that we believe specifically support the biochemical, physiological and pharmaceutical reasons underpinning this innovative clinical trial. We add to this 2011 list, the topic of the stimulation of increased expression of neurotrophic factors by statins which was not covered by Roy & Pahan in 2011 but since then, in the context of neurodegenerative diseases, has shown also to be of considerable relevance to the other pleliotropic effects of statins mentioned above.

Suppression of proinflammatory molecules and microglial activation {#sec0015}
------------------------------------------------------------------

In 2011, Roy & Pahan \[[@ref013]\] collated evidence that inflammation and oxidative stress represent important components in nigrostriatal degeneration in PD \[[@ref014]\]. At that time it was already well established that cytokines were central to the inflammatory processes that accompany various forms of acute and chronic brain injury, and many research laboratories around the world had begun to focus with therapeutic intent on PD. Ghosh et al. \[[@ref019]\] also notably found that NF-kappaB was activated within the substantia nigra pars compacta of PD patients and in MPTP-intoxicated mice. Roy and Pahan \[[@ref013]\] then discussed how statins might be harnessed to reduce neuroinflammation in a Parkinsonian context.

At that time, the evidence for this potentially important property of statins was that Pahan et al. \[[@ref021]\] had already shown *Lovastatin* inhibits NF-*κ*B, iNos expression and the proinflammatory cytokines, TNF-α, IL-1β and IL-6 in lipolysaccharide (LPS)-stimulated rat primary astrocytes. Adding to earlier work by Stanislaus et al. \[[@ref022]\], Neuhaus et al. \[[@ref023]\] using in cells taken from multiple sclerosis patients demonstrated that *Simvastatin* is more potent as an effective immunomodulatory agent than either *Lovastatin* and *Mevastatin*.

To add to this, Clarke et al. \[[@ref024]\], building on the fact that they knew statins generate powerful anti-inflammatory effects in brain, reported that *Atorvastatin* exerts these effects via IL-4, and completely independent of its cholesterol-lowering actions. These results were supported by other findings \[[@ref012]\] which showed how p21(ras) inhibits the expression of iNOS by inhibiting the activation of NF-kappaB, while Pahan et al. \[[@ref021]\] demonstrated how farnesylation can impact on these biochemical processes, and how the sphingomyelin-ceramide signaling pathway is involved with stimulating the expression of iNOS via LPS- or cytokine-mediated- activation of NF-kappaB in astrocytes. The current state of knowledge at that time on these aspects had been well described and summarized by van der Most et al. \[[@ref027]\], after which Santiago et al. \[[@ref028]\] then showed that *Simvastatin* protected striatal dopaminergic terminals against the neurotoxic damage caused by LPS, but not in an MPP+ toxic model. Liu et al. \[[@ref029]\] have recently explored how the inflammatory responses in microglia may be controlled in PD-related models and postulated, that Nur77 may be a modulator of microglia-mediated dopaminergic neurotoxicity.

Building on earlier work which showed that statins protect neurons in models of long-lasting status epilepticus and seizures, Gouveia et al. \[[@ref030]\] found that *Lovastatin* protectively decreased mRNA expression levels of the proinflammatory cytokines, IL-1β, IL-6, and TNFα in hippocampal neurons during experimental status epilepticus. Using a mouse model of Alzheimer's disease (AD), Kurata et al. \[[@ref031]\] found that, after 15--20 months of treatment, both *Atorvastatin* and *Pitavastatin* were protective of senile plaque formation, and that this protection was preceded by a reduction of proinflammatory events including levels both of activated microglia and TNF-α. This supported earlier work by Tong et al. \[[@ref032]\] who had found in amyloid precursor protein transgenic mice that Simvastatin attenuated inflammation, oxidative stress and reduced amyloid beta levels and the number of affected neurites. *Simvastatin* had also been shown to protect against tissue injury in the context of ischemia-reperfusion injury \[[@ref033]\], and in a model of cardiopulmonary bypass to protect against cerebral and systemic inflammation, neuronal loss and memory impairment \[[@ref034]\].

Using a 6-hydroxydopamine model of PD and a 3 week administration of *Simvastatin*, Yan et al. \[[@ref035]\] presented evidence that NMDA receptor modulation, MMP9 (matrix metalloproteinase-9) and TNF-α by *Simvastatin* could partially explain its anti-inflammatory, neuroprotective effects. Using a similar model of PD, Kumar et al. \[[@ref036]\] then found in a mixed behavioral and biochemical study that *Atorvastatin* (20 mg/kg) and *Simvastatin* (30 mg/kg) were both protective of weight loss, locomotor activity, and also decreased levels of the inflammatory cytokines, TNF-α and IL-6 that are characteristic of this model. They also found that these statins restored the deficits in mitochondrial enzyme complex activity that are also generated in their 6-hydroxydopamine model.

The notion that mitochondrial function might be involved with the anti-inflammatory action of statins was also highlighted by Esposito et al. \[[@ref037]\] in a completely different model, that of spinal cord injury (which also displays inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, and nuclear factor (NF)-*κ*B activation). They showed that PPAR-α (a major arbiter of mitochondrial size and number) *contributes* to the anti-inflammatory activity of *Simvastatin*. Specifically, and describing their findings as the demonstration of a new mechanism for the action of statins, they showed that the anti-inflammatory properties of *Simvastatin* were substantially reduced in a PPAR-α knockout model. Since, as well as overall mitochondrial function, the PPAR-alpha nuclear receptor also regulates genes involved with inflammation and oxidative stress, it is of particular interest that they found PPAR-α mediates the anti-inflammatory effects of *Simvastatin in vivo* models of acute neuroinflammation. This built on their earlier observation \[[@ref038]\] that *Simvastatin* similarly worked in synergy with PPAR-α to protect cellular damage caused by systemic inflammation in a model of multiple organ failure. A recent report by Zhou et al. \[[@ref039]\] expands Esposito's findings in that they showed *Simvastatin* is both neuroprotective and inhibits secondary inflammatory damage by markedly down-regulating the expression of the proteins (NF)-*κ*B, TLR4 and IL-1β.

Xu et al. \[[@ref040]\] studied how *Simvastatin* affects 6-hydroxydopamine-lesioned PC12 through regulation of PI3K/AKT/caspase 3 and by modulating inflammatory mediators, and how it might be used therapeutically to treat patients with PD. In a cellular RNA study involving 6-OHDA administration, Yan et al. \[[@ref041]\] explored the involvement of N-methyl-D-aspartic acid receptor 1 (NMDAR1) finding that *Simvastatin* inhibits the expression of NMDAR1, and of the cytokines, TNF-α, IL-1β, and IL-6, in a manner just as potent as using siRNA for the receptor. In a retinal cell model, Zhang et al. \[[@ref042]\] reported that that *Simvastatin* inhibits apoptosis following IR-induced retinal injury by inhibition of the TNF-α/NF-*κ*B pathway. With a PD therapeutic perspective in mind, Zhang's findings should be seen in the context that Malu Tansey's group had previously described \[[@ref043]\] how the TNF-α/NF-*κ*B pathway mediates chronic inflammation which, in turn may generate a reduction in Parkin levels, and thereby increasing the vulnerability for degeneration of the nigrostriatal pathway. They argued that chronic inflammation offers a clear biochemical mechanism which can promote the development of PD. Huang et al. \[[@ref044]\] recently showed in multiple models that Simvastatin ameliorated memory deficits in patients with Alzheimer's disease as well as in laboratory models of AD, and that it achieved this through reduction of mRNA expression of inflammatory cytokines and mediators as well as by improving neuronal survival, supporting earlier work by Wang et al. \[[@ref045]\].

In summary, by directly inhibiting key inflammatory processes, *Simvastatin* may therefore represent a therapeutically beneficial disease modifying agent with considerable potential to reduce the rate of PD progression.

Stimulation of endothelial nitric oxide synthase {#sec0020}
------------------------------------------------

Roy & Pahan \[[@ref013]\] also collated robust evidence \[[@ref014]\] in 2011 which supported the view that the upregulation of endothelial nitric oxide synthase (eNOS) is generated by statins via suppression of mevalonate and concomitant activation of the PI-3 kinase-AKt pathway. This built on Flint Beal's supposition \[[@ref046]\] that modulating eNOS might offer a valuable neuroprotective therapeutic approach for the treatment of PD. Statins inhibit iNOS expression, while in contrast, they stimulate eNOS-derived nitric oxide production, and this property appears biochemically unrelated to their ability to reduce cholesterol \[[@ref047]\]. Statin-induced upregulation of eNOS can be reversed by geranylgeranyl pyrophosphate (but not by farnesyl pyrophosphate) which intimates \[[@ref013]\] that Rac/Rho (rather than Ras) may be involved in the regulation of eNOS. Fulton et al. \[[@ref048]\] and Skaletz-Rorowski et al. \[[@ref049]\] demonstrated that Akt phosphorylates eNOS, while mevalonate inhibits phosphatidylinositol-3 kinase and thereby reduces Akt activation. As statins lower mevalonate levels (via inhibition of HMG-CoA reductase) it therefore seems likely that reduction of mevalonate may trigger increased eNOS production, and thereby increasing NO levels. Atorvastatin has been shown \[[@ref050]\] to promote NOS-derived nitric oxide production by reducing expression of caveolin-1, and the therapeutic implications of these HMG-CoA reductase effects of statins are still being actively clarified in cardiovascular medicine \[[@ref052]\].

A recent review by Saeedi Saravi et al. \[[@ref054]\] focuses more specifically on the potential relevance of the mevalonate pathway to the potential therapeutic benefit that statins may offer in protecting against long term neurodegeneration in PD patients. Bezard's group \[[@ref055]\] now consider downstream modulation of the sterol regulatory element-binding protein 1 (SREBP-1) pathway to be important in inducing phenotypic changes in dopaminergic cells, including increases in cell growth, synaptic connections and protein expression. They have recently presented additional data on this that supports a potential protective role of statins in PD \[[@ref056]\]. Since SREBP-1 (and SREBP-2) regulates promotor activity of PCSK9 \[[@ref057]\] there is therefore a clear link, with therapeutic implications, between SREBP-1 and PCSK9, and it was recently shown that *Simvastatin* increases PCSK9 expression \[[@ref058]\] which may be therapeutically relevant \[[@ref060]\].

Sun et al. \[[@ref064]\] showed in a cardiovascular context that eNOS is a direct target of miR-155. Inflammatory cytokines such as TNF-α increase miR-155 expression and inhibition of miR-155 reverses TNF-α-induced downregulation of eNOS expression. They found that *Simvastatin* decreased TNF-α-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-α on eNOS via the mevalonate-geranylgeranyl-pyrophosphate-RhoA signaling pathway.

Pierucci et al. \[[@ref065]\] reviewed in 2011 the promise and opportunities of harnessing the NOS system to treat PD, essentially building on the work by Hoang et al. \[[@ref066]\] who assessed the aspects and extent of the nitrative damage, including in nuclear and mitochondrial DNA, that is caused in an MPTP model of PD, and in a NOS knockout model, and from which they concluded DNA damage may contribute to the overall neurodegenerative process in PD. Peter Jenner's group \[[@ref067]\] found evidence of a major role for i-NOS-mediated nitrative stress in microglia in their MPP+ model of PD, which they concluded had important implications for developing neuroprotective strategies for PD, an argument which was further supported by Tripathy et al. \[[@ref068]\], and also recently reviewed by Jiménez-Jiménez et al. \[[@ref069]\] from the perspective of studies both in PD patients, and in various PD models.

Li et al. \[[@ref070]\] reported in 2015 how *Simvastatin* is therapeutically beneficial following LPS-induced experimental lung injury, showing it had a protective effect by alleviating lung injury via decreasing iNOS levels. This ties in with the earlier findings by Pahan et al. \[[@ref021]\] who, as described above, had already demonstrated that *Lovastatin* inhibits NF-*κ*B, iNOS expression and the proinflammatory cytokines, TNF-α, IL-1β and IL-6 in LPS-stimulated rat primary astrocytes.

Therefore, as well as its beneficial effects through suppression of proinflammatory molecules and reduction of microglial activation (as outlined in the previous section), *Simvastatin* also appears to offer substantial long-term disease-modifying benefits for PD patients on the basis of decreasing microglia iNOS levels and reducing chronic nitrative stress.

Along with the continued research into how NOS may contribute to the neurodegenerative process in PD, and may thus offer a therapeutic opportunity, such as using *Simvastatin*, to delay PD progression, a parallel line of research has explored how NOS might be modulated for therapeutic benefit in treating a widespread clinical complication experienced by many PD patients on long-term dopaminergic support, that of L-DOPA-induced dyskinesias. How NOS inhibitors might be employed in the treatment of dyskinesias has been explored in experimental studies using various PD models \[[@ref071]\], and is clearly showing promise for clinical translation for the treatment of dyskinesias in PD patients. The basis for this \[[@ref075]\] is that when inhibitors of the MAPK signaling cascade impede the inappropriate dyskinesia-inducing response of striatal neurons this offers considerable evidence that MAPK inhibitors may offer therapeutic efficacy in reducing incidence and/or severity of dyskinesias experienced by PD patients.

The isoprenylation of Ras is inhibited by statins which underpins their ability to curb the stimulation of ERK 1/2 MAP kinases, and Schuster et al. \[[@ref077]\] found that Lovastatin reduces the number and severity of dyskinesias in their 6-OHDA model of PD. In particular, Tison et al. \[[@ref078]\] found that Simvastatin was indeed effective in reducing dyskinesias in a monkey model of PD, but only at high doses that would be incompatible with their long-term administration in man, and which were 3-6 times higher than is being used in the current clinical trial of Simvastatin in PD patients (see below).

Inhibition of oxidative stress {#sec0025}
------------------------------

Roy & Pahan \[[@ref013]\] reviewed the evidence for the involvement of statins in inhibiting the process by which oxidative stress contributes to neurodegeneration in PD, particularly focusing on the roles of nicotinamide adenosine dinucleotide and Rac, collating evidence that NADPH oxidase is vital in terms of attrition of dopaminergic neurons. In fact it was already known that nigral NADPH oxidase is upregulated in MPTP mice, but that, conversely, this toxin had no effect on dopaminergic neurons in gp91phox (--/--) mice \[[@ref079]\]. Building on the review by van der Most et al. \[[@ref027]\], Roy & Pahan \[[@ref013]\] provided evidence that the inhibition by statins of the geranylgeranylation of Rac leads to reduced NADPH oxidase-mediated generation of superoxide, which they interpreted as evidence statins may attenuate oxidative stress by diminishing the production of reactive oxygen species both in the substantial nigra of MPTP mice, and in PD patients via this biochemical process.

Since then, much research has focused on the role of Nrf2 (nuclear factor erythroid 2-related factor 2) in oxidative stress \[[@ref081]\], and how, in several therapeutic areas, including PSP and PD \[[@ref083]\], age-related macular degeneration \[[@ref084]\], oncology \[[@ref085]\], cardiovascular disease \[[@ref087]\], arterial calcification \[[@ref089]\], spinal cord injury \[[@ref090]\] and radiation dermatitis \[[@ref091]\], this emerging biochemical insight might be manipulated to therapeutic advantage. Nrf2 is a cytoprotective master regulator of the transcriptional response to oxidative stress; it has a rapid turnover, and its role in neurodegenerative diseases has been well described by Gan and Johnson \[[@ref092]\], and its diversity of actions and control with respect to mitochondrial function were recently well reviewed by Holmstrom et al. \[[@ref093]\], and also by Dinkova-Kostova et al. \[[@ref094]\]. When reactive oxidative species are at low levels, nuclear Nrf2 is suppressed by the inhibitory protein, KEAP1, which sequesters Nrf2 in the cytoplasm to prepare it for proteasomal degradation \[[@ref095]\], and which maintains Nrf2 at a relatively low steady state level. However, increasing levels of reactive oxidative species influence KEAP1 in a way that progressively impairs its ability to target Nrf2 for degradation. A link between Nrf2, MAPT expression and the risk of PD has recently been postulated by Wang et al. \[[@ref097]\], and may possibly offer a mechanistic glimpse of why tau/MAPT repeatedly appears in large-scale GWAS studies of PD patients \[[@ref098]\] yet its role in the generalized risk of developing PD, and its specific role in neuroinflammation with regards to PD, are both poorly understood \[[@ref100]\].

Several agents (particularly Nrf2 activators), which act on these biochemical pathways (by upregulating antioxidant, anti-inflammatory, mitochondrial biosynthetic, apoptotic mediator and cytoprotective genes) have promising potential for the long-term protection from neurodegeneration in PD patients. These include monomethylfumarate \[[@ref101]\], dimethylfumarate \[[@ref102]\], gliptins \[[@ref103]\] and the triterpenoid, RTA-408 \[[@ref085]\], each of which have already been prioritized by the International PD Linked Clinical Trials committee to enter clinical trials in PD patients to determine their disease-modifying potential. As a practical therapeutic approach in neurology, much of the new understanding of the protective potential of activating Nrf2 resides in these emerging publications and it is being rapidly translated into disease-modifying agendas in PD, as well as in other therapeutic areas. Urate probably also acts via the Nrf2 antioxidant response pathway \[[@ref104]\] and is currently being tested (using oral inosine) in a Phase III trial in 270 PD patients to assess its disease-modifying potential over a treatment duration of 2 years \[[@ref105]\]. To add to all the other biochemical actions of statins outlined in this review we can add another LCT-prioritized drug, *Simvastatin*, to this important list of Nrf2 activators that may all have the potential to be used clinically to slow neurodegeneration in PD patients. In 2014 Abdanipour et al. \[[@ref106]\], studying PGC-1α and Nrf2 expression on cell survival and apoptosis demonstrated that *Lovastatin* protects bone marrow stromal cell-derived neural stem cells against oxidative stress-induced cell death, and suggested it as a candidate for the treatment of neurological diseases that involve oxidative stress. Since then, several papers have added further support to the view that statins act as Nrf2 activators. Wu et al. \[[@ref107]\] recently reported that *Atorvastatin* reduces damage in liver injury when exposed to inflammatory stress, citing loss of the adaptive antioxidant response mediated by Nrf2 as the basis for the biochemical mechanism involved. *Simvastatin* was found by Jang et al. \[[@ref108]\] to induce heme oxygenase-1 via direct activation of Nrf2 in human colon cancer cell lines. Ferraro et al. \[[@ref109]\] studied the effects of *Simvastatin* in both lung inflammation and in a human neuroblastoma cell line and concluded that *Simvastatin* may provide neuroprotection against neurotoxicity via Nrf2 independently of its ability to inhibit cholesterol synthesis. Furthermore, Yeh et al. \[[@ref110]\] demonstrated that the well known effect of statins to protect against atrial fibrillation was generated by the activation of Akt/Nrf2/heme oxygenase-1 signaling.

Hsieh et al. \[[@ref111]\] was the first to show that iron production from Heme oxygenase-1 activity may play an important role in the increased apoptosis in response to glucose deprivation in neuronal cells pretreated with *Simvastatin which acted by* inducing Heme oxygenase-1, a process which was mediated by Nrf2. They found in neuronal cells that the iron chelator, desferrioxamine, blocked apoptosis, which suggested that iron production from Heme oxygenase-1 activity might drive increased apoptosis in situations of glucose deprivation in neuronal cells that had been pretreated with *Simvastatin*. Two PD trials also prioritized by the international PD Linked Clinical Trials committee in 2012 are underway to test iron chelator therapy as a potential disease-modifying treatment for patients with PD. One trial involves 338 early-stage PD patients who are not currently taking antiparkinsonian medication (disease duration less than 18 months) and who are taking the iron chelator, Deferiprone \[[@ref112]\], and the second dose-finding trial \[[@ref113]\], also using Deferiprone, is comprised of 140 PD patients who have been diagnosed with PD within the last 3 years and who are currently taking antiparkinsonian medication.

Attenuation of α-synuclein aggregation {#sec0030}
--------------------------------------

In their 2011 review of the potential for using statins to treat PD, Roy and Pahan \[[@ref013]\] summarized the knowledge at that time relating to how alpha-synuclein impacts on dopaminergic toxicity and cell loss, motor deficits, the synthesis of cholesterol, and the deposition of alpha-synuclein-rich Lewy bodies in the substantia nigra. They concluded that, since statins suppress the release of proinflammatory molecules from activated glial cells (see above), it is likely they should also subdue malformed alpha-synuclein-mediated glial cell activation in a manner that is completely independent of cholesterol. As with all the other sections in this review, much has moved on over the past 6 years. A current view, held by many (but not in 2011) is that malformed alpha-synuclein is capable of cell-to-cell transmission and that this may underpin the development of PD throughout the body, but particularly involving spread from the enteric nerves, and/or olfactory bulb, to the substantia nigra, raphe, locus coeruleus, the cortex and several other important anatomical sites which each contribute in their own way to the range of PD symptoms we see clinically \[[@ref114]\].

Roy and Pahan \[[@ref013]\] reflected on how *Lovastatin*, *Simvastatin* and *Pravastatin* each generate large reductions in alpha-synuclein accumulation both in a transfected neuronal cell line, and in primary human neurons \[[@ref119]\], and that *oxidized* cholesterol even promotes increased alpha-synuclein aggregation \[[@ref120]\]. This observation has recently been somewhat supported by Eriksson et al. \[[@ref121]\] who interpreted their findings in a neuroblastoma cell line exposed to MPP^+^ to reason that high cholesterol in PD stimulates the accumulation of alpha-synuclein.

Once *Lovastatin* was also shown \[[@ref122]\] to reduce alpha-synuclein accumulation and aggregation in transgenic models, it was logical to contemplate that, since statins lower cholesterol levels, then they may therefore directly reduce the aggregation of alpha-synuclein in PD patients. Koob et al. concluded that, while it was known as early as 2006 \[[@ref123]\] that, once mutated, alpha-synuclein causes a much stronger glial cell inflammatory response, but that since statins reduce the expression of these proinflammatory molecules they may well be found beneficial as a long-term treatment for patients with PD. Given the knowledge available at that time, Roy and Pahan \[[@ref013]\] therefore posed the logical question; do statins suppress mutated alpha-synuclein-mediated glial cell activation in a manner that is completely independent of cholesterol? Several papers, mostly published since then, have gone some way to answering that question \[[@ref024]\] --the widely-held consensus answer is definitely yes, although there is still slightly less clarity on the mechanistic details than we might have wished for.

Modulation of adaptive immunity {#sec0035}
-------------------------------

Statins have been repurposed into several diseases where innate and adaptive immunity and endothelial damage play an important role \[[@ref132]\]. To date, statins have been specifically tested and used in atherosclerosis \[[@ref133]\], multiple sclerosis \[[@ref134]\], rheumatoid arthritis \[[@ref136]\], Behcet's disease \[[@ref137]\], and Kawasaki disease \[[@ref138]\] in many cases with very promising results. It was pointed out in the review by Roy & Pahan \[[@ref013]\] that effector T cells may exacerbate disease progression (which can be demonstrated in post mortem PD brains), while regulatory T cells (Tregs) tend to occupy a protective role. It has been found that T-cell responses in an MPTP model of PD add to the rate of neurodegeneration \[[@ref140]\] while conversely, Tregs have been shown to be protective in an MPTP model of PD \[[@ref143]\], and the reasons behind this duality have previously been discussed by Mosley et al. \[[@ref144]\] and, since Tregs can be modulated *in vivo*, this gives strong support to the use of an immunomodulatory approach to treat PD. In 2010, Reynolds et al. \[[@ref145]\] demonstrated that natural Tregs reversed the T cell nigrostriatal degeneration caused by malformed alpha-synuclein, proposing that this observation forms a sound rationale for future PD immunization strategies. This approach has been reviewed and expanded upon by several with considerable clarity and insight \[[@ref124]\], and most recently by Gendelman and Mosley \[[@ref148]\] who discussed approaching this topic in therapeutic terms by postulating simultaneously to seek enhancing the suppressive function of Tregs, while downregulating proinflammatory cytokine production. They balanced and tempered this by recognizing that immune system activation is also necessary in order to clear debris to help sustain and restore damaged neurons. They offered 'mounting and strong evidence' that immune transformation can affect the pathogenesis of neurodegenerative diseases, and that modulation of the inflammatory response, while restoring a homeostatic immune system via immunopharmacological strategies, may lead to new therapeutic opportunities for PD and other neurodegenerative disorders.

Acting as a cytokine and neuropeptide which impacts on immune responses, Vasoactive Intestinal Peptide (VIP) induces Tregs. The neuroprotective capability of Tregs is mediated through TH17, and it has been suggested that shifting the balance between effector and regulatory T cell activity by adaptive immune regulation of glial homeostasis could be used to attenuate neurotoxic inflammatory events \[[@ref149]\]. By peptide modifications similar to those for GLP-1 agonists that have given them greater potency and much longer metabolically stable half-life in blood than the native hormone, Olsen et al. \[[@ref150]\] developed an analogue of VIP and showed it to be an effective immunomodulatory agent in an MPTP model of PD. They concluded by stating they had provided "strong evidence" that VIP receptor agonism has the potential to slow the pathogenesis of PD through modulation of the inflammatory response. This builds on the earlier observation by Brachmachari and Pahan \[[@ref151]\] who, and citing Foxp3 as a master regulator in Treg formation and function, discovered that *Simvastatin* upregulates Foxp3 by inhibiting nitric oxide production, going on to suggest that Treg enrichment by *Simvastatin* may help to protect dopaminergic neurons in the substantia nigra.

Increased expression of neurotrophic factors {#sec0040}
--------------------------------------------

This potential biochemical effect of statins was not covered in the earlier review by Roy & Pahan \[[@ref013]\]. Hernandez-Romero et al. \[[@ref152]\], as well as demonstrating the potency of *Simvastatin* in markedly reducing inflammatory responses in LPS-induced PD rats, including interleukin-1, TGF-α and iNOS (as have several other groups, as described above), also found that *Simvastatin* stimulated the activation of the neurotrophic factor, BDNF. This suggests there may be a profoundly neurogenic aspect to the mechanism of action of *Simvastatin* in dopaminergic neurons. This was followed up by Wu et al. \[[@ref153]\] who showed that *Simvastatin* increases the hippocampal expression of BDNF and VEGF in a model of brain injury.

They concluded that the neurorestorative effect of *Simvastatin* they observed was probably mediated via the Akt-mediated signaling pathway, which thereby upregulated expression of growth factors, thus stimulating via neurogenesis the restoration of cognitive function they observed with *Simvastatin*. They employed a similar dose to that used in our current clinical trial of *Simvastatin* in PD patients (see below). It was then reported \[[@ref154]\] in a model of spinal cord injury that *Simvastatin* generated significantly improved locomotor recovery, and this improvement was ascribed to the higher levels of expression of BDNF and GDNF which were observed in this study after administration of *Simvastatin*. This contention was further supported when it was reported \[[@ref155]\] that both *Simvastatin* and *Atorvastatin* increased the expression of BDNF, VEGF and NGF, as well as activation of the Akt-mediated signaling pathway, in an experimental model of intracerebral hemorrhage. Furthermore, it was shown \[[@ref156]\] that *Simvastatin* modulates the profile of the release of cytokines and trophic factors from microglia, (particularly interleukin-1β, TNF-α, and BDNF) through a mechanism that is cholesterol-dependent, and which went some way to explain previously confusing contradictions in laboratory results. Rana et al. \[[@ref157]\] then reported that *Simvastatin* increased expression of BDNF exon-IIC transcripts in stressed mice. Wang et al. \[[@ref158]\] then reported that, in Aβ25-35-mice, *Simvastatin* is protective of neurogenesis through reduction of farnesyl pyrophosphate level which then generates α7nAChR-cascading PI3K-Akt and increased levels of BDNF. Next, Gao et al. \[[@ref159]\] demonstrated that *Simvastatin* significantly increases the levels both of BDNF and GDNF in a model of spinal cord injury, and then went on to show that *Simvastatin* also reduces neuronal apoptosis while promoting locomotor recovery in this model \[[@ref160]\]. It was recently shown \[[@ref161]\] that *Simvastatin* promoted the neurogenesis and migration of neural stem cells with a mode of action involving the ROCK/CGTase pathway. *Simvastatin* has also recently been demonstrated to improve peripheral nerve regeneration and functional recovery in an experimental model of sciatic damage that involves elevation of levels of GDNF and several other growth factors \[[@ref162]\]. Earlier this year, it was reported \[[@ref163]\] that *Atorvastatin* increased serum BDNF levels and improved functional recovery (modified Rankin and Barthel scales) in patients following atherothrombotic stroke.

It had previously been highlighted \[[@ref020]\] that the Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammatory damage, and this is thought to be particularly relevant here because Nurr1 activity is known to be closely related to GDNF activity \[[@ref164]\]. Wang et al. \[[@ref158]\] also demonstrated that *Simvastatin* induces autophagy by inhibiting the mTOR signaling pathway. In 2015, Roy et al. \[[@ref165]\] then took a step forward to help tie the various threads together in reporting that statins serve as ligands for PPARα and ascribed the neurotrophic action of statins to be via the PPARα-CREB pathway. Until then there had been no receptor protein identified for statins (they exert their *lipid-lowering* actions quite differently, more structurally, as competitive inhibitors of HMG-CoA reductase).

Finally, and here focusing on PD, unlike most of the other neurological models described in this section from which we are definitely able to draw useful parallels, Castro et al. \[[@ref166]\] reported on how *Atorvastatin* in an intranasal PD rat model caused a significant increase in striatal and hippocampal levels of nerve growth factor, adding that their findings 'extend the notion of the neuroprotective potential of *Atorvastatin* and suggest that it may represent a new therapeutic tool for the management of motor and non-motor symptoms of PD', while in 2016, Tan et al. \[[@ref167]\] showed in an LPS model of PD that *Simvastatin* restored the expression of BDNF, as well as replicating earlier findings by many groups that it reduces oxidative stress and improves nigral function.

EPIDEMIOLOGICAL STUDIES ON THE USE OF STATINS AND THE RISK OF PD {#sec0045}
================================================================

The purpose of this section is not intended as a critical appraisal of epidemiological research in this area, nor to generate data synthesis (in fact others have previously attempted to do this - see below), but rather to provide a catalogue, and a context, of published studies.

Valid interpretation of published studies has been consistently confounded by the core reason why statins are taken, i.e., to reduce high levels of cholesterol, which in turn means there is inevitably a high correlation between the two explanatory variables, statin use and blood cholesterol levels. Partly because of this confounding inter-relationship, there is currently no clarity about whether statin use is protective of an individual developing PD, has no effect, or makes it more likely that an individual may develop the disease.

Most would agree that the hypothetical risk of a healthy individual acquiring PD through taking a particular medication, represents a very different scenario to using that same medication to treat the disease once it has already developed. Nevertheless, it is appropriate to discuss here, and bring a balance to, the various studies that have either linked the taking of statins to protecting healthy individuals against developing PD, or the converse.

We re-emphasize this ongoing epidemiological debate is actually of questionable relevance to patients who *already* have PD but it is appropriate in terms of our on-going trial of Simvastatin to use this opportunity to give a balanced scientific review of the viewpoints, the available evidence, and to highlight strengths and weaknesses in published papers in this area of research.

First, it is important to make the point that, since the initial isolation of statins from microorganisms in the 1970s, there has been a huge growth in their specific use in primary and secondary prevention of various forms of cardiovascular disease. In 2016, the US Preventative Services Task Force advised the use of statins for people between 40 and 75 years old who carry at least one risk factor for heart disease, and who have more than a 10% risk of heart disease \[[@ref168]\]. Similarly, the UK National Institute for Health and Clinical Excellence has endorsed the use of statins in those with an estimated 10% risk of developing cardiovascular disease over the next decade \[[@ref169]\]. The nature, interactions and pharmacokinetic relationships between cholesterol, apolipoproteins and statins were well described from a neurological perspective in a Cochrane review \[[@ref170]\] as a part of an original, then updated, analysis to consider the possible use of statins in the context of dementia prevention or treatment. They found 'insufficient evidence to recommend statins for the treatment of dementia'. Many PD patients develop cognitive impairment, but while none of those in that meta-analysis were PD patients, a recent paper by Deck et al. \[[@ref172]\] found that PD patients taking statins performed better on tests of global cognition, semantic fluency and phonemic fluency. Furthermore, although it is known that statins increase HDL and apolipoprotein A1 levels \[[@ref173]\], and that lower apolipoprotein A1 levels are associated with later stages of PD progression, Deck did not find that baseline apolipoprotein A1 levels correlated with any baseline neuropsychological measures.

Turning now to the question of whether the use of statins may positively or negatively influence the risk of developing PD, in 2006 and citing that epidemiologic investigations had revealed an association between low LDL-C levels and the risk of PD, with several studies previously having suggested a role of lipid and cholesterol metabolism in the pathogenesis of PD, de Lau et al. \[[@ref175]\], studying \>6000 patients, felt there might well be a role involving lipids in the pathogenesis of PD, and suggested that this provided support for the notion of an important role of oxidative stress in the pathogenesis of the disease.

An extensive review of patients in the Veterans Affairs healthcare system then found *Simvastatin* (but not *Atorvastatin* or *Lovastatin*) use was associated with a strong reduction in incidence of dementia and PD \[[@ref176]\]. Wahner et al. \[[@ref177]\] then found that all statins are inversely associated with PD (except for *Pravastatin*). They observed a higher frequency of statin use among controls versus PD cases. The strongest protective association between statin use and PD was observed in long-term (\>5 yr) statin users. Huang et al. \[[@ref178]\] then reported the results of a small epidemiological study of 124 PD patients and 110 controls which inferred that low LDL-C may be associated with a higher occurrence of PD, and that statin use for prophylactic cardiovascular protection may lower PD occurrence. What Huang did not report is whether their patients had low LDL levels prior to their diagnosis of PD, nor whether their LDL levels decreased after this diagnosis. Therefore, since statins are effective at lowering LDL cholesterol levels, it may well be that their study design intrinsically confused cause with effect. What is more is that this research was vastly underpowered in the sense that fewer than 20 of the 124 PD patients in this study were actually taking statins so the results cannot be viewed as reliable. Becker at al then reported in a case-control analysis involving 3637 PD patients and 3637 controls that the long-term use of statins or fibrates was not associated with a substantially altered relative risk of developing PD \[[@ref179]\].

The same year, a study of approximately 50,000 Finnish citizens, with their baseline serum total cholesterols stratified into five groups, reported that those individuals with the highest levels of cholesterol were almost 90% more likely to develop PD than those with the lowest levels of cholesterol \[[@ref180]\], concluding that, in subjects under 55 years of age, our 'large prospective study suggests that high total cholesterol at baseline is associated with an increased risk of Parkinson's disease'.

A retrospective study involving a cohort of 419 PD patients, showed that in PD patients who received either a statin or a fibrate, their mean age of disease onset was delayed by nearly 9 years when compared with PD patients who were not taking any lipid-lowering treatment \[[@ref181]\]. They also found the increase in the levodopa-equivalent daily dose over 2 years was significantly smaller in the group taking a statin (+24 mg) than in the matched control group (+212 mg) (*p* = 0.004), whereas the UPDRS motor score progression was similar. Their conclusion was that lipid-lowering drugs may have a disease modifying effect.

The 2011 DATATOP study \[[@ref182]\] then provided evidence that higher total serum cholesterol concentrations may be associated with a modest slower clinical progression of PD. The same team at Harvard, using 12 years of patient follow-up, and following 644 documented incident cases of PD, then reported \[[@ref183]\] that regular use of statins was associated with a modest reduction in PD risk. They suggested that "the possibility that some statins may reduce PD risk deserves further consideration".

The following year Undela et al. \[[@ref184]\] conducted a robust meta-analysis of published healthy subjects and found, across five separate case-control studies (*n* = 43,526) and three cohort studies (*n* = 1.4 million), that statin use reduced an individual's risk of getting PD by 23% (*p* = 0.005), but no such effect was found for *long-term* statin use. They substantiated their findings by conducting further sensitivity analyses and concluded that their results 'suggest a decreased relative risk of PD in statin users as identified by a combined meta-analysis of eight observational studies'. Friedman et al. \[[@ref185]\] then reported their findings following 94,308 (initially) non-statin users who did not have PD. By the end of their study, there had been 1035 incident cases of PD. Furthermore, 29,714 participants (31.5%) had started using statins for a minimum of 6 months during the study period. This statin use was associated with a significant decrease in the incidence of PD (*p* = 0.001), while no association was found between baseline LDL-C levels and PD risk. Friedman felt their results provided evidence relating to a lower incidence of PD among statin users.

This contention was further supported by a report from Taiwan \[[@ref186]\] following for several years 43,810 individuals who had started taking a statin, and backed up by an excellent commentary by Tan and Tan, \[[@ref187]\]. It was found that continuation of taking lipophilic statins was associated with a decreased incidence of PD, whereas taking hydrophilic statins appeared not to generate this benefit.

Then, Huang et al. \[[@ref188]\] reported results of a prospective study involving 15,291 individuals without PD and mostly who were not statin users at study commencement. Over approximately a decade statin usage had increased to 11.2% of the study population, and there were 56 incident cases of PD. As in their 2011 paper \[[@ref182]\] they reported that higher total cholesterol was associated with a lower risk of developing PD, even after adjustment for statin use. Unlike their earlier studies they calculated that statin use may be associated with a higher risk of acquiring PD which added further uncertainty to this topic, and also attracted considerable journalistic interest.

To try to gain some clarity on whether statins were protective or not in terms of initially developing PD, Bai et al. \[[@ref189]\] and Sheng et al. \[[@ref190]\] both published extensive meta analyses of relevant results to date. Bai's meta-analysis involved 3,513,209 individuals and included 21,011 incident cases of PD. Sheng's meta-analysis involved 2,787,249 individuals. The results of both studies were in complete agreement that statin use was associated with a much lower risk of PD (*p* = 0.001) and that sensitivity analyses confirmed the robustness of these results. They found that statin use was less protective of PD in North America than in other geographies, which is something that may account for some of the conjecture and mixed results that had been published previously. Furthermore, and adding to this complexity in terms of confounding interpretation of statin use in the context of PD epidemiology, Clark et al. \[[@ref191]\] found that the frequency of treatment success in dyslipidemia management was significantly lower in African American patients in the USA than in non-Hispanic white patients, while Yood at al \[[@ref192]\] found that African American patients initiating statin therapy are less likely to achieve LDL goals, even after controlling for adherence differences and other factors, and suggested that this group may require different pharmacologic management.

Huang's group then reported in 2016 \[[@ref193]\] that higher levels of LDL-cholesterol were associated with improved executive set shifting and fine motor scores in PD patients, but not in healthy controls. This small study (64 PD cases) did not contain many statin users to be meaningful on interpreting this aspect but interestingly, they hypothesized from their results that there may possibly be an association between cholesterol and cognition that is nigrostriatal-based while very fairly pointing out that they could not currently ascertain whether this relationship was causative, reverse-causative or a parallel process.

Earlier this year Huang's group \[[@ref194]\] used a large US claims database of people who had chosen to enroll in private healthcare insurance schemes in order to interrogate this team's earlier 2015 contention \[[@ref188]\] that statin use may be linked to a higher risk of PD. This time they included 21,599 individuals who, during the period of their analysis generated 2322 incident cases of PD who, for statistical analysis, were then matched with an identical number of healthy controls. Consistent with several earlier studies, they found that higher levels of cholesterol was associated with a lower risk of PD. They also reported that the use of statins (especially lipophilic statins) was associated with higher risk of PD.

Rozani et al. \[[@ref195]\] recently published a 232,877 population-based cohort study of new statin users in whom 2,550 developed PD during a mean follow-up of 7.6 years. The study was unusual in that throughout this time the researchers comprehensively made multiple repeated measurements both of statin exposure and LDL-levels. Contrary to Huang's findings \[[@ref188]\], and agreeing with the results of many other studies \[[@ref176]\] they found no association between annual statin adherence and PD risk regardless of age, or type of statin taken.

Understandably, those taking statins, or consider taking a statin, to reduce their cardiovascular risk want to know whether this choice would also bring them an increased likelihood of developing PD? This is a very different question to whether a statin might represent a disease-modifying therapeutic for use in patients who have *already* developed PD, and our ongoing 2 year clinical trial involving approximately 200 PD patients seeks specifically to determine whether *Simvastatin* slows PD progression.

As can be seen above, there have been several epidemiological studies investigating whether there may be an association, protective or otherwise, of statin use in relation to subsequent development of PD. These have recently been evaluated in a systematic review and meta-analysis by Bykov et al. \[[@ref196]\] that helpfully discusses the methodological strengths and weaknesses of each of these earlier epidemiological studies. It is fair to say that the methodologies utilized in the epidemiological papers cited above all have limitations. Association does not imply causation. Bykov found that overall there seems to be a protective effect of statins against development of PD, but that if cholesterol levels are adjusted for, then this protective effect disappears, and there is no association one way or the other with PD development. The authors also describe some of the limitations of epidemiological study design, including the 'healthy user' and 'immortal time' biases among others \[[@ref197]\].

A brief description of the key findings from many of the various types of epidemiological studies that have attempted in recent years to determine whether the use of statins is positively or negatively associated with PD risk are summarized in [Table 1](#jpd-7-jpd171203-t001){ref-type="table"}.

###### 

Key findings from various epidemiological studies that have attempted to determine whether the use of statins is positively or negatively associated with PD risk

  Reference and Research team     Study Type &Size
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Wolozin et al. \[[@ref176]\]    Retrospective analysis of VA database of 4.5 million subjects, which included 700,000 SV users
  Huang et al. \[[@ref178]\]      Case control study involving 124 PD cases and 112 controls
  Wahner et al. \[[@ref177]\]     312 PD cases versus 343 controls. Population-based case control study of incident PD
  Becker et al. \[[@ref179]\]     Case-control observational analysis involving 3,637 PD patients (378 of whom had or were taking statins), and 3,637 controls
  Mutez et al. \[[@ref181]\]      Retrospective analysis of a cohort of 419 PD patients
  Gao et al. \[[@ref183]\]        Prospective study of 129,066 healthy subjects, 644 of whom developed PD over 12 years of follow-up
  Undela et al. \[[@ref184]\]     Meta-analysis, combining 5 case control studies and 3 cohort studies which studied 1.4 million subjects including 15,102 PD cases
  Friedman et al. \[[@ref185]\]   94,308 subjects without PD or statin use at baseline. Over 7 years, 1035 developed PD, and 29,714 took statins for at least 6 months
  Lee et al. \[[@ref186]\]        Study followed 43,810 statin users without PD, 1,985 of whom went on to develop PD
  Huang X et al. \[[@ref188]\]    Prospective study of 15,792 subjects over 9 years, 106 of whom developed PD while another 187 subjects may have developed PD but this could not be clinically confirmed
  Liu et al. \[[@ref194]\]        Retrospective case control analysis involving 2,322 probable incident PD cases and 2,322 controls. Same research team as 188
  Rozani et al. \[[@ref195]\]     Population-based cohort of statin initiators. 232,877 new statin users were followed for 7+ years, and in whom there were 2,550 emergent cases of PD
  Bai et al. \[[@ref189]\]        Meta-analysis, combining 5 case control studies and 6 cohort studies which studied 3.5 million subjects (1.1 million statin users), and including 21,011 incident cases of PD
  Bykov et al. \[[@ref196]\]      Meta-analysis, of ten eligible epidemiological studies
  Sheng et al. \[[@ref190]\]      Meta-analysis, of 11 studies (2,787,249 subjects) including 5 case-control and 6 cohort studies

Results, and outcomes measures used, are as described by the respective authors. SV, Simvastatin; AV, Atorvastatin; LV, Lovastatin; PV, Pravastatin.

With regard to Huang's most recent publication suggesting that *Simvastatin* may facilitate development of PD \[[@ref194]\], there are some key limitations which merit highlighting: large sectors of the population were not represented in the database that was analyzed (particularly the elderly, i.e., over 65 s, were excluded); and only those with private health insurance were included. It is possible that some patients in this study were misdiagnosed because the clinical details of the participants, and diagnostic confirmation, was not available to the researchers. The authors found that PD was more likely to be diagnosed within the first year or so of starting Simvastatin. However, it is well acknowledged that PD starts at least 5 years, if not 10 years before diagnosis; it has also been demonstrated by others that healthcare contacts increase in the year or two prior to diagnosis, which could be what led to their being prescribed a statin. It is well known that vascular risk factors increase risk of dementia, and it would not be unreasonable to suppose that the same might hold true for other neurodegenerative diseases. It is likely that most people taking a statin were started on it because of their vascular risk, and that this might have been the contributory factor that was identified in the study. Indeed, a UK cohort study has demonstrated worse PD severity with increased cardiovascular risk, and underutilization of statins in the PD population \[[@ref198]\]. The association of cholesterol and statins as risk factors for PD development has recently been discussed in a Lancet Neurology review by Ascherio & Schwarzschild \[[@ref104]\], which concluded that any possible association remains uncertain.

In conclusion, we reiterate, whether PD risk is increased or decreased by taking a statin to lower cardiovascular risk (and a clear future demonstration of the reality of this would be valuable and welcome), that the testing of a statin to treat PD neurodegeneration in patients who already have established PD is a completely separate and unrelated question. It therefore remains highly reasonable to pursue Simvastatin in a randomized clinical trial to test its disease-modifying potential in a population of PD patients (see biochemical/pharmaceutical rationale described earlier). In this Simvastatin trial \[[@ref007]\] we are measuring PD severity and so will pick up whether or not the rate of PD progression is affected by Simvastatin, hopefully in a positive direction as that is the point of the trial. We are carefully monitoring for adverse events and at the end of the study in 2020 we will finally be able to evaluate the unblinded data.

DESCRIPTION OF CURRENT LCT CLINICAL TRIAL OF SIMVASTATIN {#sec0050}
========================================================

No drug has yet been shown to slow or reverse the neurodegenerative process of PD. All currently licensed therapies act as symptom-relieving agents but have a limited lifespan of effectiveness because of continued neuronal loss. The purpose of *this* study, as mandated by the International PD Linked Clinical Trials Committee \[[@ref006]\], is to determine whether *Simvastatin*, a widely used cholesterol-lowering drug (statin) with an excellent safety profile, is capable of reducing the rate of neurodegenerative decline in patients with PD. Details of this clinical trial are described on the US clinical trials website \[[@ref007]\]: <https://clinicaltrials.gov/show/NCT02787590>.

Briefly, after considerable discussion about how best to configure an appropriate long-term *disease-modifying* trial in PD patients (rather than a symptomatic study), a randomized, double-blind, placebo-controlled, two year study was chosen, to be conducted in idiopathic PD patients who, at study commencement, had been characterized as Modified Hoehn and Yahr stage ≤ 3.0 in the ON medication state. It was made a requirement for entry into the trial that they were on dopaminergic treatment with wearing-off phenomenon.

Participants are randomly allocated to one of two treatment groups. In one group, participants are given capsules of *Simvastatin* to take orally (by mouth) for 24 months.

The other group receives placebo capsules to take orally for 24 months. At the start of the study, when they receive their medication, participants complete a number of questionnaires and motor (movement) tests (a walking test and a finger tapping test). Participants in both groups also attend a further 6 clinic visits after 1, 6, 12, 18 and 24 and 26 months, where they are asked about their health and any medication they are taking, as well as repeating the questionnaires and motor tests. For 4 of the clinic visits, having omitted their usual PD medication that day, the participants are asked to attend in the 'OFF medication' state so that the researchers can get a true picture of their disease without it being masked by their normal medication.

The *Simvastatin* trial is a 198 patient, 23 Centre, Phase II, randomized, placebo-controlled, double-blinded study, officially titled '*Simvastatin* as a Neuroprotective Treatment for Parkinson's Disease: a Double-blind, Randomised, Placebo Controlled Futility Study in Patients of Moderate Severity'. The primary outcome measure is Change in MDS-UPDRS part III (OFF) score, and the duration of treatment is 24 Months. The Secondary Outcome Measures include MDS-UPDRS total score in the practically defined ON state, MDS-UPDRS part II subscale score in the practically defined ON state, Timed motor tests - finger tapping and timed walk test, Timed Motor Tests include evaluating the number of hand taps that an individual can perform within 30 seconds and a timed walk test. In addition, the following rating scales are used to evaluate the study participants: Montgomery and Asberg Depression Rating Scale (MADRS), The Addenbrooke's Cognitive Assessment-III (ACE-III), Non-Motor Symptom assessment scale (NMSS), Parkinson's disease Questionnaire (PDQ-39), Changes in PD medication as measured by levodopa-equivalent dose (LED), Cholesterol levels (total, HDL, total/HDL ratio), King's PD pain scale (KPPS), EuroQoL 5D-5L health status questionnaire (EQ-5D-5L), Safety and tolerability of trial medication by adverse events (AEs) review, and Incidence of diabetes mellitus.

Active comparator: A one month low dose phase of 40 mg oral *Simvastatin* daily is followed by a 23-month high dose phase of 80 mg oral *Simvastatin* daily and a final two month phase off trial medication. Matched Placebo Comparator: A one month low dose phase of 40 mg matched placebo daily is followed by a 23 month high dose phase of 80 mg matched placebo daily and a final two month phase off trial medication.

Outline of choices made about the Simvastatin trial {#sec0055}
---------------------------------------------------

### Patient population {#sec0060}

We elected to recruit patients in mid-stage disease, H&Y \<or  = 3 in the ON state, but who had developed motor fluctuations. The reason for this was two-fold. First, we felt that the trial findings would be of relevance to people living with PD today. Second, the presence of wearing off reduces the degree of heterogeneity in the study population, particularly for ensuring, as much as possible, consistency in the 'practically-defined off' state used for the primary outcome measure.

### Study sites {#sec0065}

We selected a multi-center design as it would not be possible to recruit the required number of participants from a single center. Within the UK we have an established Clinical Research Network that facilitates study delivery within centers experienced in PD clinical study delivery. The multi-center nature of the study does introduce issues relating to quality control, particularly with regard to rater experience and training. We therefore carried out feasibility assessments with sites expressing interest, stipulating the study requirements in terms of rater uniformity for the study duration, the need for an independent rater (separate from the rest of study delivery), rater experience and training (kindly provided by the MDS for this study). In addition, the study co-ordinating center has robust data management and site monitoring processes to ensure quality data collection across all sites.

### Dose of Simvastatin chosen {#sec0070}

We chose to use a dose of 80 mg of *Simvastatin* for this study, as this was the dose shown to have an excellent protective effect in the MS STAT trial involving treating Multiple Sclerosis patients \[[@ref135]\]. There are safety concerns regarding the use of high dose *Simvastatin*, particularly in the elderly. The overall risk of statin-induced myopathy is approximately 1%. We have introduced robust guidance and safety procedures into the protocol to mitigate this risk.

### Choice of selected duration of clinical trial {#sec0075}

Study duration was chosen as 24 months to maximize the potential for differences in progression between placebo and active treatment group. It is known that the placebo effect in PD studies is large and sustained. In addition, with a relatively small sample size and a clinically heterogeneous condition, it is important to allow sufficient time for measurable disease progression across the study population.

### Choice of primary patient outcome {#sec0080}

Choice of primary outcome measure was the OFF state MDS-UPDRS part III as this is the most likely to correlate with underlying disease severity and therefore be indicative of disease progression. This does not reflect clinical meaningfulness for patients whose OFF state UPDRS score will be improved by symptomatic medication; however, demonstrating clinical utility is not the purpose of this preliminary study. If this study suggests that *Simvastatin* does have potential as a neuroprotective agent, then a further Phase III study can evaluate impact on clinically meaningful outcomes, such as patient reported measures, quality of life measures, and cognitive decline.

### Other design aspects {#sec0085}

In order to distinguish a protective effect from a potential symptomatic effect a washout design was chosen with a 2-month washout period after the end of the 24-month treatment period. The half-life of *Simvastatin* is less than 5 hours, and so this period provides sufficient time for drug elimination.

DISCUSSION {#sec0090}
==========

The international PD linked clinical trials committee, based on a range of evidence compiled into a detailed dossier, and followed by extensive committee discussions, agreed in 2012 to prioritize *Simvastatin* to enter a trial in PD patients to assess its potential as a disease-modifying therapy \[[@ref006]\]. Clinical trials of potential neuroprotective agents in PD are difficult to design. This is partially because of the variability in disease phenotype and rate of progression, and also, the potential confounding factor of a symptomatic response. In addition, there is no reliable biomarker for disease progression. The International PD Linked Clinical Trial committee is tasked to analyze potential new target therapies for PD and for which the biochemical evidence indicates the likelihood that they may have benefit to slow, halt or reverse disease progression in patients with PD. This large global committee of PD experts, many of whom have extensive experience in PD trials and their design, is coordinated by The Cure Parkinson's Trust. The detailed biochemical, physiological, and pharmaceutical evidence available to the committee in 2012 which led them to choose to prioritize *Simvastatin* to enter a disease-modifying clinical trial is summarized in the first section of the current paper, with very substantial updating to October 2017. It is interesting to observe that the rationale, then in 2012, for taking *Simvastatin* into a PD trial to assess its disease-modifying potential (in fact, there are several separate mechanistic rationales as outlined above) has continued to strengthen over those 5 years on all biochemical and physiological fronts. Another recent review by Saeedi Saravi et al. \[[@ref200]\] also summarizes, but more generally across several neurodegenerative diseases, the biochemical and pharmaceutical mechanisms of action of how statins may be beneficial in the management of these conditions. In their discussion of the treatment of multiple sclerosis they explore research into how immunomodulatory and anti-inflammatory properties of statins may helpfully unite for therapeutic benefit \[[@ref201]\] and this may also be of direct relevance to the long-term management of PD. This is especially poignant since Simvastatin has already shown encouraging long-term clinical results in patients with multiple sclerosis \[[@ref135]\], and a major Phase III study involving almost 1200 patients being given high dose Simvastatin (80 mg daily) will commence in the coming months. We have long established strong lines of communication between those involved with the multiple sclerosis (MS-STAT) and Simvastatin (PD STAT) trials.

Taking the example, also conceptually relevant to PD, of the costs of some of the newer multiple sclerosis (patented) therapeutics that are pursuing disease-modification objectives, several of these currently exceed \$75,000 per patient per year \[[@ref205]\]. By contrast, the annual cost per patient of 80 mg Simvastatin (now unpatented) is \$37 per year \[[@ref206]\], although that is not to say that the cost effectiveness of those high value therapies render them financially unusable \[[@ref207]\], as this can vary across patient subgroups which in turn means that direct therapeutic, or even financial, comparisons with Simvastatin cannot always readily be made. However, there may be situations in the future where low cost unpatented drugs like Simvastatin may look a very attractive therapeutic alternative for healthcare providers, while the patient perspective can be somewhat different and must also be taken in to account \[[@ref210]\] because health economic algorithms currently used often miss substantial additional social value.

The first, biochemical, section of this paper demonstrates that *Simvastatin* acts on a number of separate, distinct intracellular processes, each of which appear of relevance to the long-term management of PD. These remain highly active research topics and we eagerly anticipate developments into this growing insight. When a repurposed therapeutic such as Simvastatin, has multiple pleiotropic effects, all or any of which may be clinically beneficial, there sometimes comes a point when one may just acknowledge we cannot identify a clear therapeutic target (because there are so many positively-orientated candidate modes of action), and go ahead and test it in the clinic. To quote John Overington from BenevolentAI, 'although the concept of a single drug target is a natural one for researchers in the field, there are substantial operational difficulties in consistently mapping this target concept to specific genes and gene products' \[[@ref211]\]. Clearly, having a strong and extensive safety record has helped us move Simvastatin into a long-term trial in PD patients to explore its disease-modifying potential. We anticipate our current *Simvastatin* trial in PD patients will finish in 2020.
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